ABSTRACT: Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described.
We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.
Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.
Cases Journal 01/2010; 3:59.